Benzinga | Jul 19, 2021 07:01AM EDT

Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced the presentation of 14 scientific posters involving the company's ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting, which will take place from July 23-27, 2021, in Las Vegas.

"Bausch + Lomb is committed to supporting continued research on our eye health products, because we recognize this is essential to fostering the kind of peer-to-peer discussion and learning that ultimately helps promote better patient outcomes," said Joe Gordon, U.S. president, Bausch + Lomb. "While this type of scientific exchange has continued in many forms over the past year, it's particularly exciting to see it return as part of live, in-person meetings."

Ten of the presentations discuss the clinical performance of one or more of Bausch + Lomb's enVista(r), Crystalens(r) and Trulign(r) intraocular lens (IOL) platforms. Two posters will highlight the results of studies in which investigators used the cloud-based eyeTELLIGENCE(tm) clinical decision support software, which is available exclusively on the Stellaris Elite(r) vision enhancement system, to evaluate energy and fluidics metrics and analyze the impact of COVID-19 on ophthalmic surgeries. Another poster will compare the refractive astigmatism prediction accuracy of Emmetropic Verifying Optical toric calculator. A final poster will feature a clinical evaluation of the safety and efficacy of the ClearVisc(tm) dispersive ophthalmic viscosurgical device, which was approved by the U.S. Food and Drug Administration for use in ophthalmic surgery in April 2021.